​

ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

FinancialsChart
ZyVersa Therapeutics by TradingView

Previous Close

$0.77

52W Range

$0.55 - $6.70

50D Avg

$0.96

200D Avg

$1.95

Market Cap

$2.18M

Avg Vol (3M)

$2.30M

Beta

0.68

Div Yield

-

ZVSA Company Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Feb 11, 2022

Website

ZVSA Performance

ZVSA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-9.14B$-14.42M$-13.01M
Net Income$-9.41B$-98.30M$-759.10M
EBITDA$-9.14B$-107.74M$-11.67M
Basic EPS$-848.03$-1.09K$-930.25
Diluted EPS$-848.03$-1.09K$-930.25

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HEPAHepion Pharmaceuticals, Inc.
CNSPCNS Pharmaceuticals, Inc.
IMMXImmix Biopharma, Inc.
ZURAZura Bio Limited